Novo Nordisk rolls out cheaper authorised Semaglutide
Novo Nordisk South Africa is set to launch the country’s first and only authorised copy of semaglutide later…
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
Novo Nordisk will conduct a non-exclusive internal evaluation of semaglutide implants prepared by Vivani ALAMEDA, Calif., July 07,…
Minnier wins gold at powerlifting worlds | Sports
Tegan Minnier didn’t want to know what the number was; he just wanted to get the weight off…
Japanese Rare Earth Mission to Greenland Adds Geopolitical Weight to European Lithium’s Takeover V
European Lithium shareholders are heading toward a pivotal vote at the end of August, just as a Japanese…
Novo Nordisk Maps Out a Future Beyond Weight Loss, but Investors Are Counting the Days to 2027
Novo Nordisk unveils longevity and aesthetics strategy at ADA, but stock languishes as CagriSema approval not expected until…
NOVI Health Partners with Novo Nordisk to Expand Access to Structured Weight Care Support in Singapore
The collaboration aims to improve access to lifestyle coaching supported, clinically guided programs for patients exploring medical weight…
Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)
Wegovy® 7.2 mg in a single-dose pen has now been recommended by CHMP for approval in the EUNovo…
Novo Nordisk’s Two-Front Data Blitz: Oral Wegovy Scores in Weight Loss as MASH Findings Bolster th
Novo Nordisk’s oral semaglutide shows 21.6% weight loss in early responders, but stock remains 45% off highs amid…
Novo Nordisk A/S: Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity
Wegovy® showed an average 22.6% weight loss for premenopausal women with obesity, with more than 4 in 10…
Novo Nordisk A/S: Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on Obesity
Early responders (15% or more weight loss after 24 weeks) to the higher dose of Wegovy® (semaglutide 7.2…
Novo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on Obesity
Analyses of the higher dose of Wegovy® (semaglutide 7.2 mg) and Wegovy® pill (oral semaglutide 25 mg) show…
Novo Nordisk taps start-up for new oral weight-loss drugs
Fresh off the launch of its semaglutide pill, Novo Nordisk has entered a partnership with a start-up…